Protease Inhibitors

The matrix below highlights key and common point mutations associated with the development of antiretroviral drug resistance and cross-resistance to Protease Inhibitors (PI). Resistance data are included only for FDA-approved drugs and drugs available through Expanded Access Programs.

	Causes phenotypic and clinical resistance	Contributes to phenotypic and clinical resistance	Accessory Resistance Mutation	Unknown	No resistance
Increased Susceptibility
Click on drug names, colored cells and mutations for additional and specific data.



10
20
24
30
32
33
36
46
47
48
50
53
54
63
71
73
77
82
84
88
90
93